Analyst Price Targets — BIOA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 27, 2026 10:21 am | — | Needham | $50.00 | $16.15 | TheFly | BioAge Labs initiated with a Buy at Needham |
| February 18, 2026 11:08 am | Roger Song | Jefferies | $62.00 | $19.63 | TheFly | BioAge Labs upgraded to Buy from Hold at Jefferies |
| February 4, 2026 1:30 pm | — | Morgan Stanley | $23.00 | $19.99 | TheFly | BioAge Labs price target raised to $23 from $12 at Morgan Stanley |
| December 5, 2025 6:29 pm | — | Morgan Stanley | $12.00 | $11.40 | TheFly | BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley |
| March 7, 2025 1:24 pm | — | Morgan Stanley | $5.00 | $4.55 | TheFly | BioAge Labs assumed with an Underweight at Morgan Stanley |
| December 9, 2024 8:00 am | Roger Song | Jefferies | $7.00 | $4.65 | StreetInsider | Jefferies Downgrades BioAge Labs Inc (BIOA) to Hold |
| October 21, 2024 7:32 am | Samantha Semenkow | Citigroup | $45.00 | $23.86 | TheFly | BioAge Labs initiated with a Buy at Citi |
| October 21, 2024 3:37 am | Roger Song | Jefferies | $42.00 | $23.86 | StreetInsider | Jefferies Starts BioAge Labs Inc (BIOA) at Buy |
| October 21, 2024 1:37 am | Jeffrey Hung | Morgan Stanley | $40.00 | $23.86 | StreetInsider | Morgan Stanley Starts BioAge Labs Inc (BIOA) at Overweight |
Latest News for BIOA
BioAge Labs is rated Buy, leveraging strong early data for BGE-102, a novel oral NLRP3 inhibitor targeting cardiovascular and ophthalmology markets. BGE-102 achieved 86% hsCRP reduction and favorable safety in Phase 1, positioning BIOA for a pivotal Phase 2a trial in 2H 2026. BIOA holds ~$285M in cash post-raise, funding operations through 2029 and supporting multiple clinical milestones, including new obesity and…
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference taking place April 13–16, 2026.
BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report) shares dropped 6% during mid-day trading on Friday. The stock traded as low as $16.74 and last traded at $16.7160. Approximately 78,899 shares changed hands during trading, a decline of 89% from the average daily volume of 705,451 shares. The stock had previously closed at $17.79.
BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 1,341,664 shares, a growth of 47.6% from the January 29th total of 909,129 shares. Based on an average daily volume of 644,382 shares, the short-interest ratio
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BIOA.
U.S. House Trading
No House trades found for BIOA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.